Loading
A phase 3 trial of Tretinoin, Mifepristone, Alitretinoin and Tamoxifen in Breast cancer, run by Mahmoud Ramadan mohamed Elkazzaz, with a status the registry has not verified recently.
Investigating the Potential Role of a Novel Quadrate Combination Therapy Mifepristone(Antiprogestrone), Tamoxifen, Retinoic Acid and Cannabidiol ( Selective Cyp 26 Inhibitor) for Treating Early Breast Cancer is a phase 3 interventional study registered as NCT05016349 by Mahmoud Ramadan mohamed Elkazzaz, with 160 participants planned, started 2021-08 and due to reach its primary completion in 2021-10. Interventions recorded: All trans-retinoic acid, 13-Cis Retinoic Acid plus Tocopherol, Mifepristone, Cannabidiol, 9 cis retinoic acid, Tamoxifen, Standard therapy. Conditions recorded: Breast Cancer Female.
Linked to the drug Alitretinoin because the registry names it among its interventions and Breast cancer among its conditions. Registry record only: no result has been read by an editor.
Shares Mifepristone, Breast cancer (all types) and the tag pipeline.
Shares Mifepristone, Breast cancer (all types) and the tag pipeline.
Shares Tamoxifen, Breast cancer (all types) and the tag pipeline.
Shares Tamoxifen, Breast cancer (all types) and the tag pipeline.
Shares Tamoxifen, Breast cancer (all types) and the tag pipeline.
Shares Tamoxifen, Breast cancer (all types) and the tag pipeline.
Shares Tamoxifen and the tag pipeline.
Shares Tamoxifen and the tag pipeline.